Last reviewed · How we verify
NCT04683549: HPV-RICCO
HPV Serum Level and FDG PET CT in Patients With Cervical Cancer Treated With Radical Radiochemotherapy
NA trial testing HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy in Cervical Cancer in 30 participants. Status unknown.
31 May 2022
Quick facts
| Lead sponsor | The Greater Poland Cancer Centre |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 30 |
| Start date | 15 June 2020 |
| Primary completion | 31 May 2022 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- HPV serum level and FDG PET CT in patients with cervical cancer treated with radical radiochemotherapy
Conditions studied
- Cervical Cancer — all drugs for Cervical Cancer →
Sponsor
The Greater Poland Cancer Centre — full company profile →
Who can join
Adults 18 to 85, female only, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main purpose of the study is to describe changes in plasma HPV DNA levels in patients with locally advanced cervical cancer during radical radiochemotherapy (CRT) and to correlate changes with response to treatment. Monitoring of the response to treatment will also be assessed in FDG PET CT imaging.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04683549
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cervical Cancer
Currently open trials in the same condition.
- NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
- NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Other The Greater Poland Cancer Centre trials
Trials by the same sponsor.
- NCT07011316 — Subclinical Monitoring of Lymphatic Function in Oncology Patients for Lymphoedema Prevention (ONCOLYMPH) · recruiting
- NCT05715502 — Focal Salvage Brachytherapy Study (FocaSaBra) · NA · recruiting
- NCT05142202 — High Five (HiFi) Accelerated Partial Breast Irradiation Study · NA · unknown
- NCT05192447 — The Cognitive-Behavioral Dysfunctions and the Potential of Neuroplasticity in Brain Tumors Patients During Radiotherapy · NA · unknown
- NCT06190600 — Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04683549 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Greater Poland Cancer Centre
- Last refreshed: 8 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04683549.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing